Even though substantial gene transcription in breast tumors is controlled by the PR, we focused on antagonizing only the estrogen receptor since PR expression is heavily dependent on ER expression where only 1–2% of breast tumors are known to be ER-PR+ [21, 22]. The gene discussed is ESR1; the disease is breast neoplasm.